Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 194

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 194
---
 a registered direct offering, net of offering costs of $397

    759

    1

    50,602

    —

    —

    50,603

    Issuance of common stock through ATM facilities, net of commissions and offering costs of $168

    493

    —

    9,312

    —

    —

    9,312

    Exercise of pre-funded warrants

    9

    —

    —

    —

    —

    -

    RSU settlements, net of shares withheld

    314

    —

    (7
    )

    —

    —

    (7
    )

    Issuance of common stock pursuant to employee stock awards

    26

    —

    230

    —

    —

    230

    Stock-based compensation expense

    —

    27,001

    —

    —

    27,001

    Net loss

    —

    —

    —

    (85,403
    )

    (85,403
    )

    Unrealized gain (loss) on available-for-sale securities

    —

    —

    212

    —

    212

    Balance as of December 31, 2024

    5,859

    $
    1

    $
    1,957,261

    $
    8

    $
    (2,054,553
    )
     
    $
    (97,283
    )

See accompanying notes to the consolidated financial statements.

101

Atara Biotherapeutics, Inc.

Consolidated Statements of Cash Flows

(In thousands) 

    Year Ended December 31,

    2024

    2023

    Operating activities

    Net loss
     
    $
    (85,403
    )
     
    $
    (276,126
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Stock-based compensation expense

    27,001

    45,386

    Depreciation and amortization expense

    5,051

    4,829

    Accretion of liability related to sale of future revenues

    4,109

    4,792

    Non-cash operating lease expense

    12,126

    11,795

    Amortization (accretion) of investment premiums

    (240
    )

    792

    Other non-cash